RUBICON RESEARCH Q2 FY27 CONCALL: RAISES FY27 OPERATING EBITDA MARGIN GUIDANCE TO 24%+ FROM 23%+ EARLIER & 22–23% INITIALLY; EXPECTS STRONG REVENUE MOMENTUM, TARGETS ₹500 CR R&D INVESTMENT THROUGH Q1 FY28, IND0RE FACILITY REVENUE FROM FY28 & COMMERCIALIZATION OF NEW FDA-APPROVED PRODUCTS